Search results for "Steatosis"

showing 10 items of 248 documents

Is there an ‘ideal’ diet for patients with NAFLD?

2021

Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic that encompasses three distinct clinical phenotypes: uncomplicated fatty liver, non-alcoholic steato-hepatitis (NASH) and NASH-related cirrhosis with its complications, including hepatocellular carcinoma. To date, no pharmacological treatments have been approved and lifestyle modifications including reduced caloric intake targeting a 7-10% weight loss from baseline assessment represent the standard approach. Mediterranean Diet has been recommended as the best dietary pattern since it is easy to follow and, independently of caloric intake its nutritional components have beneficial metabolic effects that not only improve steatosi…

medicine.medical_specialtyMediterranean dietmedicine.medical_treatmentClinical Biochemistrychronic liver disease; diet; dietary regimen; lifestyle intervention; nonalcoholic steatohepatitisChronic liver diseaseBiochemistryGastroenterologyNon-alcoholic Fatty Liver DiseaseWeight lossInternal medicineIntermittent fastingmedicineHumansnonalcoholic steatohepatitischronic liver disease diet dietary regimen lifestyle interventionnonalcoholic steatohepatitisbusiness.industryFatty liverchronic liver diseasedietary regimenlifestyle interventionGeneral Medicinemedicine.diseasedigestive system diseasesmedicine.symptomMetabolic syndromeSteatosisdietbusinessKetogenic dietEuropean Journal of Clinical Investigation
researchProduct

The use of normothermic machine perfusion to rescue liver allografts from expanded criteria donors

2021

The use of expanded criteria donors is one of the strategies used to overcome the gap between the demand for organs and the number of donors. Physicians debate the extent to which marginal grafts can be used. In recent years, normothermic machine perfusion (NMP) has been used to test liver viability before transplantation. Grafts underwent NMP whenever histological steatosis was > 40% or there were at least three Eurotransplant criteria for expanded criteria donor (ECD). We used NMP to test 19 grafts, 3 from donation after type 3 controlled cardiac death (DCD), and 16 from donation after brain death (DBD). Only two grafts from DBD were not transplanted, because perfusion proved they were…

medicine.medical_specialtyNormothermic machine perfusionmedicine.medical_treatmentLiver transplantationExpanded Criteria DonormedicineOverall survivalHumansMachine perfusionLiver transplantationbusiness.industryGraft SurvivalOrgan Preservationmedicine.diseaseAllograftsTissue DonorsDonation after brain deathSurgeryTransplantationPerfusionGraft viabilitysurgical procedures operativeLiverExpanded criteria donors Graft viability Hypothermic machine perfusion Liver transplantation Normothermic machine perfusionSurgerySteatosisExpanded criteria donorsbusinessPerfusionHypothermic machine perfusion
researchProduct

Towards a Rapid Screening of Liver Grafts at the Operating Room Using Mid-Infrared Spectroscopy

2020

The estimation of steatosis in a liver graft is mandatory prior to liver transplantation, as the risk of graft failure increases with the level of infiltrated fat. However, the assessment of liver steatosis before transplantation is typically based on a qualitative or semiquantitative characterization by visual inspection and palpation and histological analysis. Thus, there is an unmet need for transplantation surgeons to have access to a diagnostic tool enabling an in situ fast classification of grafts prior to extraction. In this study, we have assessed an attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopic method compatible with the requirements of an operatio…

medicine.medical_specialtyOperating RoomsGraft failureTime FactorsSpectrophotometry Infraredmedicine.medical_treatmentgraft failureassessmentLiver transplantation010402 general chemistry01 natural sciencesPalpationMid infrared spectroscopyAnalytical Chemistryliver steatosisLiver steatosisstomatognathic systemliver graftmedicinesteatosisHumansmedicine.diagnostic_testliver transplantationChemistryPhysics010401 analytical chemistrymedicine.disease0104 chemical sciences3. Good healthLiver TransplantationLiver graftTransplantationAtomic Molecular and Optical Physicslipids (amino acids peptides and proteins)RadiologySteatosisinfiltrated fat
researchProduct

Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento ( I ). Enfermedad del hígado graso no alcohólico…

2017

Non-alcoholic fatty liver disease (NAFLD) comprises a series of histologically lesions similar to those induced by alcohol consumption in people with very little or no liver damage. The importance of NAFLD is its high prevalence in the Western world and, from the point of view of the liver, in its gradual progression from steatosis to steatohepatitis, cirrhosis, and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with acceleration of arteriosclerosis and events related to it, being the main cause of its morbidity and mortality. This review, updated to January 2016, consists of two parts, with the first part analysing the associa…

medicine.medical_specialtyPathologyCirrhosisHigh prevalencebusiness.industryFatty livernutritional and metabolic diseasesArteriosclerosis030204 cardiovascular system & hematologymedicine.diseaseGastroenterologydigestive system diseases03 medical and health sciences0302 clinical medicineInternal medicinemedicine030211 gastroenterology & hepatologyPharmacology (medical)Liver damageSteatosisSteatohepatitisCardiology and Cardiovascular MedicineLiver cancerbusinessClínica e Investigación en Arteriosclerosis
researchProduct

Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado gr…

2017

Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influe…

medicine.medical_specialtyPathologyCirrhosisbusiness.industryDisease030204 cardiovascular system & hematologymedicine.diseaseGastroenterologydigestive system diseases03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineNonalcoholic fatty liver diseasemedicine030211 gastroenterology & hepatologyPharmacology (medical)Liver damageSteatosisSteatohepatitisCardiology and Cardiovascular MedicineLiver cancerbusinessClínica e Investigación en Arteriosclerosis
researchProduct

The “geographic” liver

2018

medicine.medical_specialtyRadiological and Ultrasound Technologybusiness.industryUrologyGastroenterologyHepatologyMagnetic Resonance Imaging030218 nuclear medicine & medical imagingFatty Liver03 medical and health sciences0302 clinical medicineText miningLiver030220 oncology & carcinogenesisInternal medicineFamily medicineLiver MRI SteatosisHumansMedicineRadiology Nuclear Medicine and imagingSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedbusinessAbdominal Radiology
researchProduct

Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: A real-life study

2019

Background:Conventional glucocorticoid treatment has a significant impact on liver in patients with adrenal insufficiency. Dual-release hydrocortisone (DR-HC) provides physiological cortisol exposure, leading to an improvement in anthropometric and metabolic parameters. We aimed to evaluate the effects of 12-month DR-HC treatment on the hepatic steatosis index (HSI), a validated surrogate index of hepatic steatosis, in patients with secondary adrenal insufficiency (SAI).Methods:A total of 45 patients with hypopituitarism, 22 with hypogonadism, hypothyroidism, ACTH, and GH deficiencies, and 23 with hypogonadism, hypothyroidism, and ACTH deficiency, on replacement therapy for all the pituitar…

medicine.medical_specialtySecondary adrenal insufficiencyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypopituitarismHepatic steatosilcsh:Diseases of the endocrine glands. Clinical endocrinologyHypopituitarismSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenal insufficiencyIn patientHydrocortisoneOriginal Researchlcsh:RC648-665business.industryhepatic steatosismedicine.diseaseInsulin sensitivityEndocrinology030220 oncology & carcinogenesisDual-release hydrocortisoneSteatosisLife studybusinessGlucocorticoidmedicine.drugSecondary adrenal insufficiency
researchProduct

GLP-1 receptor agonists in NAFLD.

2017

IF 4.101; International audience; Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.

medicine.medical_specialtySteatosisEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesGastroenterologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyFibrosisWeight lossInternal medicineInternal MedicineHumansHypoglycemic AgentsMedicineReceptorGlucagon-like peptide 1 receptorGLP-1 receptor agonistsbusiness.industryFatty livernutritional and metabolic diseasesGeneral Medicine[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseFibrosisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030211 gastroenterology & hepatologytype 2 diabetesSteatosismedicine.symptombusinessNon-alcoholic fatty liver disease
researchProduct

Higher cardiometabolic risk in idiopathic versus autoimmune type 1 diabetes: A retrospective analysis

2018

Abstract Background Idiopathic type 1 diabetes mellitus (IDM) is characterized by an onset with insulinopenia and ketoacidosis with negative β-cell autoimmunity markers and lack of association with HLA. The aim of the study is to compare the clinical and metabolic parameters, the macro and microvascular complications, the adipose tissue dysfunction and the insulin secretion and sensitivity indexes in patients with IDM and autoimmune type 1 diabetes mellitus (ADM) at clinical onset. Methods Thirty patients with IDM and 30 with ADM, matched for age and gender, were retrospectively analyzed. BMI, waist circumference, lipids, glycemia, HbA1c, insulin requirement, glutamic oxaloacetic and glutam…

medicine.medical_specialtyType 1 diabetemedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissue030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologyCardiovascular risk factorSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusmedicineInternal Medicinec-Peptideslcsh:RC620-627Cardiovascular risk factorsType 1 diabetesC-Peptidebusiness.industryInsulinResearchInsulin secretionInsulin resistancemedicine.diseaseKetoacidosislcsh:Nutritional diseases. Deficiency diseasesType 1 diabetesSteatosisC-Peptides; Cardiovascular risk factors; Insulin resistance; Insulin secretion; Type 1 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolismbusiness
researchProduct

Fatty liver indexandhepatic steatosis index for prediction ofnon-alcoholic fatty liver disease in type 1 diabetes

2017

Background and Aim Little is known about the diagnostic value of hepatic steatosis index (HSI) and fatty liver index (FLI), as well as their link to metabolic syndrome in type 1 diabetes mellitus. We have screened the effectiveness of FLI and HSI in an observational pilot study of 40 patients with type 1 diabetes. Methods FLI and HSI were calculated for 201 patients with type 1 diabetes. Forty patients with FLI/HSI values corresponding to different risk of liver steatosis were invited for liver magnetic resonance study. In-phase/opposed-phase technique of magnetic resonance was used. Accuracy of indices was assessed from the area under the receiver operating characteristic curve. Results Tw…

medicine.medical_specialtyType 1 diabetesWaistHepatologyReceiver operating characteristicbusiness.industryfungiFatty liverGastroenterologymedicine.diseaseLikelihood ratios in diagnostic testingNephropathy03 medical and health sciences0302 clinical medicineEndocrinology030220 oncology & carcinogenesisInternal medicinemedicine030211 gastroenterology & hepatologyMetabolic syndromeSteatosisbusinessJournal of Gastroenterology and Hepatology
researchProduct